ROCKLAND, Mass., Feb. 4, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Elizabeth Varki Jobes, Esq. joined the company as Senior Vice President, Chief Compliance Officer North America. In this role, Ms. Jobes will oversee the strategic direction of EMD Serono's comprehensive compliance program. She will serve as a member of EMD Serono's leadership team, as well as a member of the Global Compliance Healthcare team led by Betania Glorio, Global Compliance Officer, Healthcare, Merck KGaA, Darmstadt, Germany.
"It's an exciting time to be at EMD Serono as we prepare to introduce new therapies into practice and advance existing standards of care," said Rehan Verjee, President of EMD Serono and Global Head of Innovative Medicine Franchises, Merck KGaA, Darmstadt, Germany. "I am very pleased to welcome Elizabeth at this time given her significant experience in supporting companies like ours achieve on this mission."
Prior to joining EMD Serono, Ms. Jobes served as Global Chief Compliance Officer and Legal Counsel at Spark Therapeutics, Inc., where she was responsible for building a corporate compliance program supporting the launch of the first-approved gene therapy in the United States.
Previously, Ms. Jobes held leadership positions across a number of biopharmaceutical companies, including Senior Vice President, Chief Compliance Officer for Auxilium Pharmaceuticals, Inc.; Vice President, Chief Compliance Officer for Adolor (Cubist) Corporation; and Senior Director, Global Compliance for Cephalon, Inc. Ms. Jobes also spent a number of years working in the Philadelphia District Attorney's Office, first as a trial attorney, then as assistant chief and chief across various units.
She earned her J.D. from Rutgers University School of Law and her B.A. from Pennsylvania State University.
About EMD Serono, Inc.
EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada – is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. Today, the business has approximately 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a vibrant science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases, to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the company's business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Melissa Beglin 781-681-2609
SOURCE EMD Serono